Diabetic Nephropathy

Size: px

Start display at page:

Download "Diabetic Nephropathy"

Willis Horn
5 years ago
Views:

1 Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo Nordisk, Pfizer, Sanofi

2 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary- for your reading pleasure at home

3 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary

4 Definition of Diabetic Nephropathy Persistent albuminuria (>300 mg/24 hr or 200 µg/min) is the hallmark of diabetic nephropathy that can be diagnosed clinically if the following additional criteria are fulfilled presence of diabetic retinopathy and absence of clinical or laboratory evidence of other kidney or renal tract disease. This clinical definition of diabetic nephropathy is valid in types 1 and 2 diabetes (pg 1283) only 50% to 60% of proteinuric type 2 diabetic patients have retinopathy. (pg 1300) Brenner and Rector's The Kidney, 39, e14 Diabetic kidney disease is usually a clinical diagnosis made based on the presence of albuminuria and/or reduced egfr in the absence of signs or symptoms of other primary causes of kidney damage. The typical presentation of diabetic kidney disease is considered to include a long-standing duration of diabetes, retinopathy, albuminuria without hematuria, and gradually progressive kidney disease. However, signs of CKD may be present at diagnosis or without retinopathy in type 2 diabetes, and reduced egfr without albuminuria has been frequently reported in type 1 and type 2 diabetes and is becoming more common over time as the prevalence of diabetes increases in the U.S. American Diabetes Association- Diabetes Care Volume 40, Supplement 1, January 2017

5 Definition of Diabetic Nephropathy prevalence of albuminuria in patients with T2DM decreased from about 21% in to 16% in , despite a rise in the prevalence of reduced egfr CJASN 12: ,2017

6 DM Nephropathy Not Just a Glomerular Disease Diabetic Classic Kimmelstiel-Wilson nodule Thickened renal arterial wall

7 Pathologic Classification of DM Nephropathy

8 Pathologic Classification of DM Nephropathy IFTA = Interstitial fibrosis and tubular atrophy

9 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary

10 Estimating GFR- Cr, Age, Race, Sex The MDRD GFR is an estimate of the glomerular filtration rate (GFR) using serum creatinine and demographic factors. It has not been studied extensively in populations that are not white or black. It relies on a stable creatinine and may be less accurate for GFR values above 60. simplified MDRD equation by Levey, et. al. egfr = 186*(0.742 if female)*(1.212 if Black)*creatinine *age The CKD-EPI GFR is an estimate of the glomerular filtration rate (GFR) using serum creatinine and demographic factors. It is a relatively new equation proposed to be superior to the MDRD GFR equation. The CKD-EPI equation by Levey, et. al.: egfr = 141 x min(scr/k, 1) a x max(scr/k, 1) x Age x [if female] x [if black] Scr is serum creatinine, k is 0.7 for females and 0.9 for males, a is for females and for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1 Levey AS, Greene T, Kusek J, Beck GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: A0828, 2000 Levey et al.a new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:

CKD Stages < 30 mg/day 30-300 mg/day > 300 mg/day <

11 CKD Stages < 30 mg/day mg/day > 300 mg/day < 20 ug/min ug/min > 200 ug/min UAE ACR Albumin/min

12 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary

13 Pathogenic processes in DN and potential targeting strategies under clinical investigation. Bioorganic & Medicinal Chemistry Letters Volume 26, Issue 18, 15 September 2016, Pages

14 Potential Mechanisms for the Development of DM Nephropathy A Target Rich Environment Journal of Advanced Research Volume 8, Issue 4, July 2017, Pages

15 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary

16 What Do Most Studies Evaluate? A Specific Organ System such as Cardiac or Renal For Renal Studies What Are the Usually Measured End Points? Proteinuria Doubling of Serum Creatinine Development of ESRD What do we Really Want to Accomplish with Treatment of Diabetes Improve morbidity Improve mortality

17 Life Cycle of Diabetic Nephropathy in T1DM and 3 Points of Intervention A2- microalbuminuria to A3- Macroalbuminuria (diabetic nephropathy) A3- macroalbuminuria (DN) to ESRD Type 1 DM Changing nomenclature A1-normoalbuminuria to A2- microalbuminuria microalbuminuria = moderately increased albuminuria (A2) macroalbuminuria = severely increased albuminuria (A3)

18 Potential Issues with Studies T1DM vs. T2DM What phase is being studied- primary prevention, secondary prevention, tertiary prevention Only about 30% of diabetic patients develop DN- thus in primary prevention studies about 70% of enrolled patients will NOT develop the disease no matter the treatment. Need for better biomarkers of which patients are at risk for DN Sex differences- young males worse outcomes. Estrogen protective? Is the study drug s mechanism of action independent of glycemic and/or BP control

19 Is Albuminuria an Appropriate Surrogate Marker of Renoprotection? Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View Clin J Am Soc Nephrol Jun 5; 10(6): Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View Clin J Am Soc Nephrol Jun 5; 10(6): reduction in albuminuria observed during the first months of treatment with these drugs correlates with the degree of long-term renal protection: the larger the initial reduction in albuminuria, the lower the risk of ESRD during treatment. In addition, in treated patients, residual albuminuria is again the strongest risk marker for renal disease progression. These observations combined provide a strong argument that albuminuria is an appropriate therapeutic target in patients with CKD combining renin-angiotensin system therapies decreases albuminuria without significant clinical benefit but with increased risk of adverse events albuminuria has not jumped the hurdle needed to be accepted as a surrogate end point or target for treatment. Primum non nocere, first do no harm.

20 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary

21 Primary Care Treatment Make the Dx of DN When to Test For Albuminuria T1DM- 5 years after Dx of DM (sooner if poor control and/or hypertensive) T2DM- upon Dx of DM Disease-a-Month Volume 61, Issue 9, September 2015, Pages

Primary Care Make the Dx of DN If you do not look for a disease you will never find it vol 1 Figure 2.

years) patients without a diagnosis of CKD, by year from 2005 to 2015 (a) Medicare 5% Data Source:

Optum Clinformatics patients aged 22-64 years. Tests tracked during each year.

22 Primary Care Make the Dx of DN If you do not look for a disease you will never find it vol 1 Figure 2.3 Trends in percent of patients with testing of urine albumin (a) in Medicare 5% sample (aged 65+ years) patients without a diagnosis of CKD, by year from 2005 to 2015 (a) Medicare 5% Data Source: Special analyses, Medicare 5% sample aged 65 and older with Part A & B coverage in the prior year and Optum Clinformatics patients aged years. Tests tracked during each year. Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension Annual Data Report Volume 1 CKD, Chapter 2 22

23 Primary Care Treatment Make the Dx of DN The lack of albuminuria does not exclude DN When to Test For egfr egfr T2DM T1DM 90 yearly at Dx then yearly starting at year yearly yearly q3 months q3 months q6-8 weeks q6-8 weeks <15 q4 weeks q4 weeks My opinion

24 Primary Care Make the Dx of DN If you do not look for a disease you will never find it Figure 2.3 Trends in proportion of patients (b) serum creatinine testing, by year, among Medicare patients aged 65+ WITHOUT a diagnosis of CKD, (b) Serum Creatinine Data Source: Special analyses, Medicare 5 percent sample, aged 65 and older with Part A & B coverage in the prior year. Tests tracked during each year. Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension. USRDS Vol 1, CKD, Ch

25 Primary Care Treatment- General Measures Weight Loss Smoking Cessation Modest Protein Restriction 0.8 mg/kg Lipid Management Uric Acid Management Acidosis Management Journal of Advanced Research Volume 8, July 2017 pg J Diabetes Res. 2015; 2015: doi: /2015/ Canadian Journal of Diabetes Volume 39, Issue 3, June 2015, Pages BMC Nephrol. 2015; 16: 58. doi: /s z

26 Primary Care Treatment Glycemic Control and BP Control

27 Primary Care Treatment- BP

28 Primary Care Treatment- BP

29 Primary Care Treatment- BP

30 Primary Care Treatment- BP

31 Classic Study Showing ACEI is Renoprotecitve NEJM 1993;329:

32 ACEI For Renoprotection- CKD Stage is Important NEJM 1993;329:

33 Primary Care Treatment- BP

34 What is the Optimal BP for Patients with Diabetic Nephropathy?

35 Primary Care Treatment- Glucose

36 Intensive Glucose Control in T1DM NO Retinopathy Albuminuria < 40 mg/day A2 Retinopathy Albuminuria mg/day A2 A3 A3 N Engl J Med 1993; 329: September 30, 1993DOI: /NEJM

37 Summary of Intense Glycemic Control in T2DM Thus, as a whole, the intensity of glycemic control should probably be tempered in patients with T2DM who also have multiple comorbid conditions, with the goal of moderate glycemic control (HbA1C 7 8 %), since the benefits, if any, are hard to achieve, come with risk, and are at best small in magnitude. Intensive glycemic control with HbA1C <7 % should be attempted with extreme caution and only in younger, newly diagnosed patients without comorbidities. Update on Glycemic Control for the Treatment of Diabetic Kidney Disease Curr Diab Rep (2015) 15: 42 DOI /s

38 Intensive Glucose Control in T2DM

39 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary

40 CKD Patients Are More Likely to Die Than Progress to ESRD Percentage Who Remained Event-Free vs Death vs Developed ESRD During 5-Year Follow-up % of Patients 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 15% 16% 10% 7% 28% 64% 63% 75% 20% 1% 46% 20% 24% 10% Stage 1 Stage 2 Stage 3 Stage 4 Disenrolled Event free RRT Died Keith et al. J Am Soc Nephrol. 13:620A, 2002.

41 CKD Patients Are More Likely to Die Than Progress to ESRD Percentage Who Remained Event-Free vs Death vs. Developed ESRD During 2-Year Follow-up. Patients had their first Nephrology consult at an outpatient clinic 100% 80% % of Patients 60% 40% 20% 0% 90% 84% 1% 8% 12% No DM, No CKD 4% 68% 11% 61% 18% 20% 22% DM, No CKD No DM, CKD DM, CKD Status at Entry Period Event Free ESRD Death Medicare 5% sample , Two year follow-up, adjusted for age, gender, and race Analysis performed by Minneapolis Medical Research Foundation

population, 1980-2012 (a) Incident Cases IC (b) Incidence Rates IR Data Source: Reference tables A.

42 vol 2 Figure 1.7 Trends in (a) ESRD incident cases, in thousands, and (b) adjusted* ESRD incidence rate, per million/year, by primary cause of ESRD, in the U.S. population, (a) Incident Cases IC (b) Incidence Rates IR Data Source: Reference tables A.1, A.2(2). *Adjusted for age, sex, and race. The standard population was the U.S. population in Abbreviation: ESRD, end-stage renal disease. Simple Mathematical Example- Incident Cases (IC) vs Incident Rate (IR) Population 1,000,000 5,000,000 New Patients (IC) 1,000 3,750 Incident Rate/Million (IR) 1, USRDS 2014 Vol 2, ESRD, Ch 1 42

43 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary

44 Are SGLT2 Inhibitors Renal Protective Canagliflozin Placebo Total

45 Remember Is the Patient better off Not are one or two organ systems better off CONCLUSIONS In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.

46 Proposed Mechanism Of Action Hyperglycemia & SGLT2 Inhibitors In Diabetics Tubuloglomerular feedback:impact of low salt intake and SGLT2 inhibitors. UF = glomerular ultrafiltrate; SGLT = sodium glucose transporter; PCT = proximal convoluted tubules; DCT = distal convoluted tubule; MD = macula densa; AMP = adenosine monophosphate; VD = vasodilation; AA = afferent arteriole Journal of Advanced Research Volume 8, Issue 4, July 2017, Pages

47 Are GLP-1 Agonists Renoprotective?

48 Proposed Mechanism Of Action DPP-4 GLP insulin secretion inflammation Angiotensin II DPP-4 mediated renal fibrosis. DPP4 = dipeptyl peptidase-4; TGFβ = transforming growth factorβ; EndMT = endothelial-mesenchymal transition Journal of Advanced Research Volume 8, Issue 4, July 2017, Pages

49 Incretin Dependent Incretin INDEPENDENT

50 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary- for your reading pleasure at home

51 Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. Thank You Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo Nordisk, Pfizer, Sanofi

52 Review of Potential New Treatments for DN Selected References Therapies on the Horizon for Diabetic Kidney Disease Curr Diab Rep (2015) 15: 111 DOI /s Diabetic nephropathy: What does the future hold? Int Urol Nephrol (2016) 48: DOI /s y Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update European Journal of Pharmacology Volume 791, 15 November 2016, Pages 8-24 Management of diabetic nephropathy: Recent progress and future perspective Diabetes & Metabolic Syndrome: Clinical Research & Reviews 9 (2015) Diabetic nephropathy: landmark clinical trials and tribulations Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411

53 Approved Treatments for DM Nephropathy Journal of Advanced Research Volume 8, Issue 4, July 2017, Pages

56 Major DN Studies Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411

57 Major DN Studies Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411

58 Major DN Studies Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411

59 Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411 Major DN Studies

Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D.

Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. llehrner@ksosn.com Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo